Jay Zoellin’s research project aims to address a critical gap in current medical care: Researchers at IOB recently discovered that a previously overlooked mutation is potentially the most common genetic defect in inherited retinal diseases. However, despite the high prevalence of this condition, both disease models and therapeutic options for affected individuals are still missing. Zoellin’s project involves establishing models that accurately recapitulates the disease’s pathogenesis and leveraging advanced gene therapy techniques to address this gap and develop an effective treatment.
Stefan Futterknecht’s research focuses on advancing gene therapies for retinal diseases. His project aims to explore innovative treatments that can potentially halt or reverse the progression of these debilitating conditions. His work seeks to pave the way for new therapeutic approaches that could significantly improve the quality of life for patients suffering from retinal diseases.
The national MD-PhD grants program, supported by private foundations and in collaboration with the Swiss School of Public Health, has been awarding these grants annually since 1992. This highly competitive grant recognizes outstanding young physicians with a commitment to research, providing them with the skills necessary for a dual career as both clinician and scientist. Grants are awarded for a period of up to 3 years, providing the necessary resources for in-depth and impactful research.
Warm congratulations to Jay Zoellin and Stefan Futterknecht. This grant recognition does not only highlight their exceptional research potential but also underscores IOB’s commitment to fostering innovative solutions in ophthalmology. Their work promises to push the boundaries of our understanding and treatment of retinal diseases.
